Furat Cevdet, İlhan Gökhan, Bayar Ekrem, Bozok Şahin, Güvener Murat, Yılmaz Mustafa
Departments of Cardiovascular Surgery, Hacettepe University Medicine Faculty, Ankara, Turkey.
Departments of Cardiovascular Surgery, Recep Tayyip Erdoğan University Medicine Faculty, Rize, Turkey.
Turk Gogus Kalp Damar Cerrahisi Derg. 2018 Jan 9;26(1):22-29. doi: 10.5606/tgkdc.dergisi.2018.14620. eCollection 2018 Jan.
This study aims to evaluate the effect of L-carnitine on postoperative cardiac performance and morbidity and complications in patients undergoing coronary artery bypass grafting.
Between April 2005 and June 2008, a total of 60 patients (36 males, 24 females; mean age 60.6 years; range 57 to 65) who were scheduled for coronary artery bypass grafting were prospectively randomized to receive one of three different strategies of myocardial preservation. Group A (n=20) received antegrade crystalloid cardioplegia, Group B (n=20) received antegrade blood cardioplegia, and Group C (n=20) received antegrade blood cardioplegia with carnitine. Samples for lactate dehydrogenase (LDH), creatinine phosphokinase (CPK), creatinine phosphokinasemyocardial band (CK-MB), and Troponin-I were taken from coronary sinus during the operation and from peripheral venous line postoperatively. Blood samples were obtained before CPB, just after CPB and postoperative 1, 6, 12, 24 and 48 hours. Levels of CPK, CK-MB and Troponin-T levels were studied by immunoassay method.
The patients who received carnitine had significantly improved cardiac output, cardiac index, and right and left ventricular stroke work immediately after cardiopulmonary bypass and at the first postoperative hour (p=0.01). Troponin-T levels decreased in all patients after 12 hours postoperatively, and this change was most prominent in Group C (p=0.001).
Intravenous supplementation of carnitine during cardioplegia provides better results on the recovery of cardiac function and metabolic parameters after coronary artery bypass grafting.
本研究旨在评估左旋肉碱对冠状动脉搭桥术患者术后心脏功能、发病率及并发症的影响。
在2005年4月至2008年6月期间,共有60例计划进行冠状动脉搭桥术的患者(36例男性,24例女性;平均年龄60.6岁;范围57至65岁)被前瞻性随机分配接受三种不同的心肌保护策略之一。A组(n = 20)接受顺行晶体心脏停搏液,B组(n = 20)接受顺行血液心脏停搏液,C组(n = 20)接受含肉碱的顺行血液心脏停搏液。术中从冠状窦采集乳酸脱氢酶(LDH)、肌酸磷酸激酶(CPK)、肌酸磷酸激酶心肌带(CK-MB)和肌钙蛋白-I样本,术后从外周静脉采集。在体外循环前、体外循环刚结束时以及术后1、6、12、24和48小时采集血样。采用免疫分析法研究CPK、CK-MB和肌钙蛋白-T水平。
接受肉碱治疗的患者在体外循环后及术后第1小时的心输出量、心脏指数以及左右心室每搏功均有显著改善(p = 0.01)。术后12小时所有患者的肌钙蛋白-T水平均下降,且C组变化最为显著(p = 0.001)。
心脏停搏期间静脉补充肉碱对冠状动脉搭桥术后心脏功能和代谢参数的恢复效果更佳。